Compugen (CGEN) Other Accumulated Expenses (2020 - 2021)
Compugen recorded quarterly Other Accumulated Expenses of $4.8 million in Q4 2021, down 2.91% quarter-over-quarter from $4.9 million in Q4 2020, and down 2.91% year-over-year from $4.9 million in Q4 2020.
Compugen's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $4.8 million for Q4 2021.
- In Q4 2021, Other Accumulated Expenses fell 2.91% year-over-year to $4.8 million; the TTM figure through Dec 2021 stood at $4.8 million (down 2.91% YoY), while the FY2021 annual figure was $4.8 million, down 2.91% from the prior year.
- Other Accumulated Expenses came in at $4.8 million for Q4 2021 at Compugen, down from $4.9 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q4 2020 to a low of $4.8 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compugen | 234.03 Mn | 142.28 Mn | 352,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 4.78 Mn |
| Dec 31, 2020 | 4.92 Mn |